References
[1] Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197.
[2] Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
[3] Golchin N, Patel A, Scheuring J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulm Med. 2025;25(1):378.
[4] King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-1961.
[5] Gandhi S, Tonelli R, Murray M, et al. Environmental causes of idiopathic pulmonary fibrosis. Int J Mol Sci. 2023;24(22).
[6] Jiang M, Bu W, Wang X, et al. Pulmonary fibrosis: from mechanisms to therapies. J Transl Med. 2025;23(1):515.
[7] Sekine A, Hagiwara E, Oda T, et al. High prevalence of upper lung field pulmonary fibrosis radiologically consistent with pleuro-parenchymal fibroelastosis in patients with round atelectasis. Respir Investig. 2023;61(6):738-745.
[8] Li B, Wang J, Zhao Y, et al. Vitamin D3 reverses immune tolerance and enhances the cytotoxicity of effector T cells in coal pneumoconiosis. Ecotoxicol Environ Saf. 2024;271:115972.
[9] Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873-1881.
[10] Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J. 2016;48(1):187-195.
[11] Harari S, Madotto F, Caminati A, et al. Epidemiology of idiopathic pulmonary fibrosis in northern Italy. PLoS One. 2016;11(2):e0147072.
[12] Pardo A, Selman M. Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2016;13 Suppl 5:S417-S421.
[13] Yao C, Guan X, Carraro G, et al. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. Am J Respir Crit Care Med. 2021;203(6):707-717.
[14] Jin H, Park SY, Lee JE, et al. GTSE1-driven ZEB1 stabilization promotes pulmonary fibrosis through the epithelial-to-mesenchymal transition. Mol Ther. 2024;32(11):4138-4157.
[15] Fang D, Chen B, Lescoat A, et al. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol. 2022;18(12):683-693.
[16] Liu Q, Zaba LC, Satpathy AT, et al. Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis. Nat Commun. 2020;11(1):5843.
[17] Sang L, Guo X, Fan H, et al. Mesenchymal stem cell-derived extracellular vesicles as idiopathic pulmonary fibrosis microenvironment targeted delivery. Cells. 2022;11(15).
[18] Mutsaers SE, Miles T, Prele CM, et al. Emerging role of immune cells as drivers of pulmonary fibrosis. Pharmacol Ther. 2023;252:108562.
[19] Inui N, Sakai S, Kitagawa M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-beta and the ubiquitin-proteasome pathway. Int J Mol Sci. 2021;22(11).
[20] Schafer MJ, White TA, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.
[21] Karampitsakos T, Woolard T, Bouros D, et al. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2017;808:35-43.
[22] Bhandari R, Ball MS, Martyranov V, et al. Profibrotic activation of human macrophages in systemic sclerosis. Arthritis Rheu-matol. 2020;72(7):1160-1169.
[23] Matsuyama W, Watanabe M, Shirahama Y, et al. Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis. Am J Pathol. 2006;168(3):866-877.
[24] Gabasa M, Duch P, Jorba I, et al. Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis. Mol Biol Cell. 2017;28(26):3741-3755.
[25] Niu H, Guo F, Li W. Stilbene glucoside prevents PM2.5 caused pulmonary fibrosis by pseudo hypoxia, autophagy and NF-kappaB signal pathways. Int Immunopharmacol. 2025;156:114674.
[26] Pavlides S, Tsirigos A, Vera I, et al. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the “reverse Warburg effect”: a transcriptional informatics analysis with validation. Cell Cycle. 2010;9(11):2201-2219.
[27] Zank DC, Bueno M, Mora AL, et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics. Front Med (Lausanne). 2018;5:10.
[28] Park WH. The mitochondrial nexus: dysfunction, inhibition, and therapeutic frontiers in lung disease. Respir Med. 2025;250: 108506.
[29] Guo F, Xu F, Li S, et al. Amifostine ameliorates bleomycin-induced murine pulmonary fibrosis via NAD+/SIRT1/AMPK pathway-mediated effects on mitochondrial function and cellular metabolism. Eur J Med Res. 2024;29(1):68.
[30] Wang L, Yuan H, Li W, et al. ACSS3 regulates the metabolic homeostasis of epithelial cells and alleviates pulmonary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2024;1870(2):166960.
[31] Kim SJ, Cheresh P, Jablonski RP, et al. The role of mitochondrial DNA in mediating alveolar epithelial cell apoptosis and pulmonary fibrosis. Int J Mol Sci. 2015;16(9):21486-21519.
[32] Tu M, Wei T, Jia Y, et al. Molecular mechanisms of alveolar epithelial cell senescence and idiopathic pulmonary fibrosis: a narrative review. J Thorac Dis. 2023;15(1):186-203.
[33] Geng J, Liu Y, Dai H, et al. Fatty acid metabolism and idiopathic pulmonary fibrosis. Front Physiol. 2021;12:794629.
[34] Tang X, Li G, Shi L, et al. Porcine respiratory disease complex induces pulmonary fibrosis related to the aberrant sphingolipid metabolism. Int J Exp Pathol. 2025;106(5):e70005.
[35] Gu L, Larson Casey JL, Andrabi SA, et al. Mitochondrial calcium uniporter regulates PGC-1alpha expression to mediate metabol-ic reprogramming in pulmonary fibrosis. Redox Biol. 2019;26:101307.
[36] Li G, Zhang Y, Jiang H, et al. PPARG/SPP1/CD44 signaling pathway in alveolar macrophages: mechanisms of lipid dysregulation and therapeutic targets in idiopathic pulmonary fibrosis. Heliyon. 2025;11(1):e41628.
[37] Budinger GRS. Alveolar macrophage-fibroblast crosstalk includes a feedforward arginase 1/IL-6 circuit implicated in pulmonary fibrosis. J Clin Invest. 2025;135(21):e185044.
[38] Shen L, Yi Z, Liu J, et al. Identification of key genes associated with idiopathic pulmonary fibrosis and sarcopenia by bioinformatics analysis. PLoS One. 2025;20(12):e0335067.
[39] Yan P, Liu J, Li Z, et al. Glycolysis reprogramming in idiopathic pulmonary fibrosis: unveiling the mystery of lactate in the lung. Int J Mol Sci. 2023;25(1):247.
[40] He J, Dong R, Yue H, et al. SIK2 drives pulmonary fibrosis by enhancing fibroblast glycolysis and activation. Biomedicines. 2025;13(8):1921.
[41] Tian Y, Duan C, Feng J, et al. Roles of lipid metabolism and its regulatory mechanism in idiopathic pulmonary fibrosis: a review. Int J Biochem Cell Biol. 2023;155:106361.
[42] Li J, Zhai X, Sun X, et al. Metabolic reprogramming of pulmonary fibrosis. Front Pharmacol. 2022;13:1031890.
[43] Wu W, Zhang G, Qiu L, et al. Contribution of adiponectin/carnitine palmityl transferase 1A-mediated fatty acid metabolism during the development of idiopathic pulmonary fibrosis. Oxid Med Cell Longev. 2022;2022:5265616.
[44] Chen M, Meng X, Zhu Y, et al. Cathepsin K aggravates pulmonary fibrosis through promoting fibroblast glutamine metabolism and collagen synthesis. Adv Sci (Weinh). 2025;12(34):e13017.